Therapeutic Strategies for the Management of HCV/HIV co- infection

HCV/HIV 合并感染的治疗策略

• 批准号: 8156833
• 负责人: Anthony S. Fauci
• 金额: $ 94.34万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8156833
• 关键词: Albumins; Effectiveness; Future; HIV; HIV Infections; Hepatitis C; In Vitro; Infection; Monitor; Therapeutic; base

Recent advances in the treatment and monitoring of HIV infection have substantially reduced rates of HIV-associated illness and mortality; however, the management of HIV-infected patients has become increasingly complex. We are conducting studies to (1) evaluate novel therapeutic strategies for managing hepatitis C virus (HCV) infection in HIV-co-infected individuals, and (2) identify critical host factors that can predict an HIV-infected individuals response to existing HCV treatments and/or future therapies. This past year, we (1) determined the safety, tolerability and effectiveness of a novel regimen of twice monthly albumin-interferon alpha 2b plus ribavirin to treat Hepatitis C in HIV co-infected individuals; (2) demonstrated the distinct influence of ongoing HIV replication on host immune activation profiles in patients co-infected with Hepatitis C; (3) demonstrated the effect of race and baseline immune status (CD4+ T-cell count) on response rates to HCV therapy using pegylated interferon-alpha and ribavirin, (4) evaluated novel anti-HCV agents (IL-27, IL-28 and IL-29) in vitro using a newly developed HCV continuous culture system, and (5) demonstrated the role of individual Interferon-inducible gene products in controlling HCV replication in vitro.

艾滋病毒感染治疗和监测方面的最新进展大大降低了艾滋病毒相关疾病的发生率和死亡率；然而，艾滋病毒感染者的管理变得越来越复杂。我们正在进行研究，以 (1) 评估管理 HIV 合并感染者丙型肝炎病毒 (HCV) 感染的新治疗策略，以及 (2) 确定可以预测 HIV 感染者对现有 HCV 治疗和/或未来治疗反应的关键宿主因素。去年，我们 (1) 确定了每月两次白蛋白-干扰素 α 2b 加利巴韦林治疗 HIV 合并感染者丙型肝炎的新疗法的安全性、耐受性和有效性； (2) 证明了持续的 HIV 复制对丙型肝炎合并感染患者宿主免疫激活谱的明显影响； (3) 证明了种族和基线免疫状态（CD4+ T 细胞计数）对使用聚乙二醇化干扰素-α 和利巴韦林的 HCV 治疗反应率的影响，(4) 使用新开发的 HCV 连续培养系统在体外评估了新型抗 HCV 药物（IL-27、IL-28 和 IL-29），以及 (5) 证明了个体干扰素诱导基因产物在 控制HCV体外复制。